Skip to main content

Table 1 Patient characteristics according to time of TMZ failure for the entire population

From: A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

Variable B0 B1 B2 B3 All
Number of pts 20 50 45 48 163
Age years
Median (range) 59.5
(50 -65)
57.5
(47 - 64)
57
(49 - 66)
57
(47 - 65)
57
(47 - 66)
Gender % (N)
 Male 70 (14) 64 (32) 64.4 (29) 70.8 (34) 66.9 (109)
 Female 30 (6) 36 (18) 35.6 (16) 29.2 (14) 33.1 (54)
Type of Surgery at diagnosis % (N)
 Biopsy 0 4 (2) 2.2 (1) 2.1 (1) 2.5 (4)
 Partial 55 (11) 36 (18) 44.4 (20) 39.6 (19) 41.7 (68)
 Complete 45 (9) 60 (30) 53.3 (24) 58.3 (28) 55.8 (91)
RPA at baseline % (N)
III 5 (1) 14 (7) 17.8 (8) 31.3 (15) 19 (31)
IV 90 (18) 68 (34) 73.3 (33) 66.7 (32) 71.8 (117)
V 5 (1) 18(9) 8.9 (4) 2 (1) 9.2 (15)
Number of adjuvant TMZ
Cycles, Mean (range) 0 3 (2 – 4) 9 (7 – 11) 6.5 (6 – 11) 6 (2 – 8)
Time after end of radiation
Months, Mean (range) 1
(0.7 - 1.2)
4.2
(3.1 - 5.1)
8.9
(6.7 - 11.4)
14.1
(10.7 - 25.7)
6.8
(3.9 - 12)
Surgery at recurrence % (N)
 No 95 (19) 88 (44) 80 (36) 75 (36) 82.8 (135)
 Yes 5 (1) 12 (6) 20 (9) 25 (12) 17.2 (28)
FTM induction dosage (mg/m2)
Median (range) 95
(80– 100)
100
(80 – 100)
100
(80 – 100)
75
(75 – 100)
100
(75 – 100)
FTM administration number
Median (range) 4 (3 – 11) 4 (1 – 18) 3 (1 – 18) 5 (1 – 20) 4 (1 – 20)
  1. FTM: fotemustine TMZ: temozolomide; RPA: recursive partitioning analysis; B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.